Heterogeneous Ensembles for Predicting Survival of Metastatic, Castrate-Resistant Prostate Cancer Patients

F1000Research - United Kingdom
doi 10.12688/f1000research.8231.1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

F1000 Research Ltd

Related search

Management of Docetaxel Failures in Metastatic Castrate-Resistant Prostate Cancer

Urologic Clinics of North America
Urology
2012English

Evidence for the Efficacy of Enzalutamide in Postchemotherapy Metastatic Castrate-Resistant Prostate Cancer

Therapeutic Advances in Urology
Urology
2013English

Molecular Drivers of Metastatic Castrate-Resistant Prostate Cancer: New Roads to Resistance

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2018English

Guidelines for the Management of Castrate-Resistant Prostate Cancer

Journal of the Canadian Urological Association
OncologyUrology
2010English

Guidelines for the Management of Castrate-Resistant Prostate Cancer

Canadian Urological Association Journal
Urology
2013English

Prognostic Value of 18f-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Docetaxel

Contrast Media and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2019English

New Therapeutics to Treat Castrate-Resistant Prostate Cancer

The Scientific World Journal
BiochemistryMedicineGeneticsMolecular BiologyEnvironmental Science
2013English

Phase I Study of Anti-Cd3 X Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients

Prostate Cancer
Cancer ResearchOncologyUrology
2015English

Sipuleucel-T: Autologous Cellular Immunotherapy for Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

Journal of Cancer
Oncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy